奥密克戎时代血液学患者的抗病毒与单克隆抗体联合治疗 - Suppr

Antiviral and Monoclonal Antibody Combination Therapy in Haematological Patients in the Omicron Era.

作者信息

Vita Serena, Giombini Emanuela, De Marco Patrizia, Rueca Martina, Gruber Cesare Ernesto Maria, Beccacece Alessia, Scorzolini Laura, Mazzotta Valentina, Pinnetti Carmen, Caputi Priscilla, Focosi Daniele, Girardi Enrico, Antinori Andrea, Maggi Fabrizio, D'Abramo Alessandra, Nicastri Emanuele

机构信息

National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS-Rome Italy.

North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

出版信息

Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024043. doi: 10.4084/MJHID.2024.043. eCollection 2024.

DOI:10.4084/MJHID.2024.043

PMID:38882452

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11178048/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca0c/11178048/4d6c85c0cf61/mjhid-16-1-e2024043f1.jpg

相似文献

Antiviral and Monoclonal Antibody Combination Therapy in Haematological Patients in the Omicron Era.奥密克戎时代血液学患者的抗病毒与单克隆抗体联合治疗

Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024043. doi: 10.4084/MJHID.2024.043. eCollection 2024.

Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study.奥密克戎时代抗病毒药物联合抗刺突单克隆抗体治疗与单药治疗对轻度至中度SARS-CoV2感染的高危免疫功能低下患者的疗效和安全性：一项前瞻性队列研究

Int J Antimicrob Agents. 2024 Mar;63(3):107095. doi: 10.1016/j.ijantimicag.2024.107095. Epub 2024 Jan 18.

Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.免疫功能低下患者中持续的SARS-CoV-2感染促进病毒快速进化：回顾性队列研究与文献综述

Clin Infect Pract. 2022 Nov;16:100210. doi: 10.1016/j.clinpr.2022.100210. Epub 2022 Nov 16.

Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series.在奥密克戎时代，序贯或联合治疗作为免疫功能低下的持续性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者的挽救疗法：病例系列

Antibiotics (Basel). 2023 Sep 19;12(9):1460. doi: 10.3390/antibiotics12091460.

Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染：使用 casirivimab 和 imdevimab（REGN-COV2）单克隆抗体联合治疗后成功清除。

Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.

Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。

Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.

Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.成功治疗四例免疫功能低下患者的持续性 SARS-CoV-2 感染，使用奈玛特韦/利托那韦加索托维单抗。

J Chemother. 2023 Nov;35(7):623-626. doi: 10.1080/1120009X.2023.2196917. Epub 2023 Apr 27.

Viral dynamics of SARS-CoV-2 in immunocompromised patients.免疫功能低下患者体内 SARS-CoV-2 的病毒动力学。

Clin Microbiol Infect. 2023 Aug;29(8):1087.e1-1087.e3. doi: 10.1016/j.cmi.2023.05.013. Epub 2023 May 13.

Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.系统评价和荟萃分析：替沙格韦单抗/西加韦单抗用于预防免疫功能低下患者 COVID-19 的临床效果。

Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.

Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.分离具有广谱中和活性的人源单克隆抗体，针对包括奥密克戎变异株在内的多种 SARS-CoV-2 病毒。

Antiviral Res. 2022 May;201:105297. doi: 10.1016/j.antiviral.2022.105297. Epub 2022 Mar 24.

引用本文的文献

Comparative Effectiveness of Antiviral Agents and Monoclonal Antibodies for Early SARS-CoV-2 Therapy in Immunocompromised Patients: A Multicenter Retrospective Cohort Study (March 2021-March 2022).免疫功能低下患者早期新冠病毒治疗中抗病毒药物和单克隆抗体的比较疗效：一项多中心回顾性队列研究（2021年3月至2022年3月）

Microorganisms. 2025 May 6;13(5):1076. doi: 10.3390/microorganisms13051076.

Effectiveness of early intervention and combination treatment with monoclonal antibodies and antivirals in oncohematological patients with SARS-CoV-2: a retrospective experience.早期干预以及单克隆抗体与抗病毒药物联合治疗对感染SARS-CoV-2的肿瘤血液学患者的有效性：一项回顾性研究经验

Front Immunol. 2025 Mar 28;16:1524525. doi: 10.3389/fimmu.2025.1524525. eCollection 2025.

本文引用的文献

B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience.持续感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的B细胞耗竭患者：联合治疗还是单药治疗？一项真实世界经验

Front Med (Lausanne). 2024 Feb 29;11:1344267. doi: 10.3389/fmed.2024.1344267. eCollection 2024.

Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.联合抗病毒治疗作为严重急性呼吸综合征冠状病毒2感染期间异基因造血干细胞移植的有效可行选择：一例病例报告

Front Oncol. 2024 Feb 13;14:1290614. doi: 10.3389/fonc.2024.1290614. eCollection 2024.

Int J Antimicrob Agents. 2024 Mar;63(3):107095. doi: 10.1016/j.ijantimicag.2024.107095. Epub 2024 Jan 18.

Early combination therapy of COVID-19 in high-risk patients.COVID-19 高危患者的早期联合治疗。

Infection. 2024 Jun;52(3):877-889. doi: 10.1007/s15010-023-02125-5. Epub 2023 Nov 29.

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab.用瑞德西韦、奈玛特韦/利托那韦和替沙格韦单抗/西加韦单抗联合治疗免疫功能低下患者的持续性新冠病毒感染。

J Microbiol Immunol Infect. 2024 Feb;57(1):189-194. doi: 10.1016/j.jmii.2023.09.004. Epub 2023 Sep 27.

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan.日本爱知县单中心回顾性研究：瑞德西韦联合单克隆抗体与瑞德西韦单药治疗轻中度 COVID-19 合并免疫抑制患者的比较有效性和安全性的真实世界经验。

Viruses. 2023 Sep 19;15(9):1952. doi: 10.3390/v15091952.

Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study.免疫功能低下的无症状或轻症 COVID-19 患者的靶向治疗结局：一项回顾性研究。

Sci Rep. 2023 Sep 16;13(1):15357. doi: 10.1038/s41598-023-42727-5.

Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.

Correction: The unmet need for COVID-19 treatment in immunocompromised patients.更正：免疫功能低下患者对COVID-19治疗的未满足需求。

BMC Infect Dis. 2023 Jan 31;23(1):61. doi: 10.1186/s12879-023-08034-0.

Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients.旨在完全抑制新冠病毒肺炎患者肺部严重急性呼吸综合征冠状病毒2的协同药物组合。

PLoS One. 2022 Nov 10;17(11):e0276751. doi: 10.1371/journal.pone.0276751. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Antiviral and Monoclonal Antibody Combination Therapy in Haematological Patients in the Omicron Era.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献